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Abstract 
Recognition of paediatric autoimmune/ immune-mediated encephalitis and epileptic 
encephalopathy (e.g. NMDAR-Ab encephalitis) has rapidly increased over the last ten years. 
While we are succeeding in the diagnosis and identification and even early treatment of these 
encephalitidies, with studies describing >80% are making a “good” recovery, we are now 
recognising that a “good” medical outcome does not cover the cognitive, social and behavioural 
sequelae that can occur, particularly in paediatric patients. Basic measures of medical outcome, 
for example the modified Rankin Scale (MRS) or the Paediatric Cerebral Performance Category 
(PCPC), offer the advantage of being quick to use, but do not reveal the more complex difficulties 
that can impact the future of affected children. This article reviews the current literature on 
neurodevelopmental outcomes in children affected with autoimmune and immune-mediated 
encephalitis/ epileptic encephalopathy and provides guidance on post-onset surveillance aimed at 
identifying those most likely to experience ongoing long-term difficulties. 
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Introduction 
Immune-mediated/ autoimmune epileptic encephalopathy (AEE) is characterized by the presence 
of neuronal autoantibodies that bind to proteins essential for normal brain function and 
development. When synaptic proteins are targeted (e.g. the NMDA receptor), paediatric patients 
present with a range of neurological and neuropsychiatric symptoms including seizures, movement 
disorder, and behavioural change. Acute demyelinating events (e.g. optic neuritis, transverse 
myelitis) occur with encephalopathy and seizures when autoantibodies are directed against myelin 
associated proteins, i.e. myelin oligodendrocyte (MOG). Regardless of their differing autoantibody 
targets, paediatric AEEs all have the potential to cause long-term adverse neurodevelopmental 
changes as well as the severe acute neurological and neuropsychiatric syndromes. This review 
briefly summarises the diagnosis and treatment of the common peadiatric AEEs and then focuses 
on current knowledge regarding neurodevelopmental outcomes. 
N-methyl-D-aspartate receptor antibody (NMDAR-Ab) encephalitis  
NMDAR-Ab encephalitis was first described in 2007 as a paraneoplastic neuroimmune disorder 
primarily affecting young women with ovarian teratoma1.  It is now widely recognised as the most 
common AEE, and has been described in patients of all ages, with and without the presence of 
tumours. Affected patients present with seizures, neuropsychiatric symptoms, cognitive and 
autonomic dysfunction, movement disorder and decreased level of consciousness 2. In children, 
seizures, abnormal movements, insomnia, and irritability are the more frequent symptoms 
recognised, whereas in adults, abnormal behavior and psychosis are more likely to herald the onset 
of disease 3. In pre-school children, abnormal behavior may initially be misdiagnosed as another 
neurodevelopmental disorder such as autism 4. Estimated incidence in UK children is 0.85 per 
million children per year 5, and paediatric cases make up over a third of reported cases in the 
literature 3. Diagnosis is made on the basis of clinical features and the detection of NMDAR-
antibodies directed against the NRI subunit in the cerebrospinal fluid (+/- serum) of affected 
patients 6. The EEG is almost always abnormal showing focal or diffuse slowing/encephalopathy, 
epileptic activity, or extreme delta brush 3, 7, 8. Brain MRI is only reported as abnormal in 
approximately 33% of patients, and not associated with clinical severity or neurological outcome 
3.  However, this disparity is explained by functional MRI and connectivity studies which do 
demonstrate abnormalities in hippocampal and frontoparietal network connectivity despite the 
majority having unremarkable routine brain MRI 9.   
The standard treatment regime for paediatric AEE including NMDAR-Ab encephalitis begins with 
first-line immunotherapy (e.g. steroids, immunoglobulins or plasma exchange), escalating rapidly 
to second line agents if there is no sign of clinical improvement (e.g. rituximab, 
cyclophosphamide). Although early use of rituximab in paediatric CNS autoimmune and 
inflammatory diseases is associated with improved outcomes 10, no randomized controlled trial 
evidence currently exists that compares the stepwise immunotherapy approach to initiation of 
rituximab from day of diagnosis. 
Recovery and outcomes in paediatric NMDAR-Ab encephalitis are measured primarily through 
basic assessment criteria, for example, the five point modified Rankin scale (mRS) 3, 5, 7. With 
early recognition and prompt treatment, a significant neurological improvement is seen in up to 
85% of paediatric patients using theses scales 3, 5.  More recently, however, smaller retrospective 
paediatric studies with more detailed functional and neuropsychological outcomes have been 
published and rather worryingly, suggest that compared to adults, children with NMDAR-
Ab encephalitis may have long-term effects impacting daily life 11. Using the Adaptive Behaviour 
Assessment System (ABAS-3), this study showed that pediatric patients had changes in adaptive 
behaviour that were not captured when focusing on neurological disability using the mRS scale. 
The differences in adaptive behavior observed suggested that children may be left with long-term 
impairment following NMDAR-Ab encephalitis, whereas adults assessed in a comparable way 
appeared to regain normal function. Subtle neurocognitive deficits may have affected the adaptive 
behavior resulting in an increased likelihood for affected children to require additional support at 
home and/or school for everyday living. Data from a larger retrospective study of 28 paediatric 
patients seen at a median of 31 months after disease, found that many patients had cognitive 
problems and fatigue, and this was associated with lower academic achievement and poorer quality 
of life 12. Lower scores were recorded in the sustained attention, speed and short –term verbal 
memory and language domains. Surprisingly, important predictors for “good” mRS outcomes (e.g. 
early treatment) were not associated with neuropsychological outcome, again emphasising the 
notion that mRS scales do not reflect the complete picture of recovery. One recent prospective 
study of 10 children found deficits in all domains tested in the acute phase of illness (general 
intellectual abilities, receptive and expressive language, short-term verbal memory, planning, 
selective and sustained attention and visual-motor integrations)13. During subsequent follow-up, 
general intellectual abilities were within normal limits at the most recent assessment (median 31 
months). Nevertheless, specific cognitive deficits were still present in over half of the patients at 
the same time-point, mainly affecting verbal fluency, working memory, executive functions and 
short-term memory. These persisting deficits affected quality of life, social relationships and 
academic achievement, but despite this, all children resumed their everyday lives 13. A small series 
of six children (6 to 13 years at first assessment) tested within one month of discharge through to 
24 or more months also highlighted the presence of early impairments in executive skills and 
information processing speed that persisted at long-term follow up in up to half of cases 14. Visual 
motor functions were also impaired and in a seventh case assessed first at 18 months of age, deficits 
emerged over the course of two years.  Most longitudinal studies do show improvement in 
cognitive processing over time which is encouraging for patients and families. However, the 
concern is that while patients report that their children have no residual difficulties, cognitive 
impairments that impact on social and academic functioning are still detected on formal testing 15. 
It is unclear whether this represents true deterioration, perhaps reflecting late-effects of the incident 
neurological event or its treatment, or rather a failure to attain developmentally appropriate skills 
in line with peers. The latter phenomenon is well recognized in the paediatric neuropsychology 
literature and this “early vulnerability”16 highlights the need to understand the specific profile of 
outcomes in children with AEE. This in turn underscores the importance of clinicians being aware 
of the long-term persistence of neuropsychological deficits in children following NMDAR-Ab 
encephalitis, in order to counsel families and recommend access to neuropsychology testing. Given 
the relative paucity of high quality studies in the area, it is difficult to recommend a comprehensive 
set of assessments for this cohort of children. However, based on existing findings, referral for 
age-appropriate measurement of general intellectual abilities, new learning, executive functions 
and information processing speed seems warranted. Furthermore, screening for behavioural 
impairments, again with age appropriate measures of symptomatology, is appropriate. The timing 
of assessments should be planned for key transition points in the young person’s education (into 
primary school, transition to secondary and/or further education). 
Ideally, early recognition of neuropsychological deficits will allow timely, specific interventions 
aimed to improve long-term neurodevelopmental outcomes and support families of children with 
impairments to receive tailored input from school and allied health services. Further prospective 
longitudinal studies are required to identify which children are likely to experience 
neurodevelopmental sequelae, as well as the effect of treatment on subsequent brain development. 
The other autoantibodies associated with childhood AEE along with available outcome data are 
summarized in Table 1 below.  
 





Clinical features and pediatric outcome data 
GABAA 
receptors 
Severe autoimmune encephalitis with refractory seizures and extensive MRI cortical/subcortical 
FLAIR abnormalities17, 18. Antibodies bind to co-expressed α1/β3 or α1, γ2 subunits18, 19. Strong 
association with underlying tumour in adults. 
Most patients, including children, present with refractory status epilepticus or seizures, as well 
as varying symptoms of memory, cognitive and affective problems, and movement disorder 17. 
Only one child made a complete recovery in this series of 10 cases (8/10 partial recovery; 1/10 
death)18. 
Cases also described of Febrile Infection-Related Epilepsy Syndrome (FIRES), a devastating 
epilepsy of childhood 20. Early treatment with immunotherapy is associated with improved 
outcomes in children21, 22. 
LGI1 The Leucine-rich glioma inactivated 1 (LGI1) protein is complexed to the voltage gated 
potassium channel (VGKC-complex) which functions to control membrane excitability. Found in 
adults with facio-brachial dystonic seizures, which can evolve into limbic encephalitis (LE) 
without prompt recognition and treatment23. 
One case report of 14 year old boy with Type 1 diabetes mellitus presenting with subacute 
memory dysfunction, left hippocampal swelling on imaging, and positive oligoclonal bands in 
the cerebrospinal fluid. Good recovery with plasma exchange and immunotherapy, although 
residual memory problems remained24. 
GABAB 
receptor 
Seizure predominant limbic encephalitis phenotype, associated with small-cell lung carcinoma 
in adults, very rare in children25. Single paediatric case, aged 3 years, presented with mixed 




Limbic encephalitis phenotype, rare in adults and children. One 14 year old patient described 
with favourable outcome post immunotherapy (mRS of 1) 27. Two cases of childhood onset 
Rasmussen encephalitis (RE) positive for AMPAR-Abs, likely to be secondary to inflammatory 
changes rather than causative; both had a very typical course of RE28. 
Glycine 
receptor 
Most commonly associated with Progressive encephalomyelitis with rigidity and myoclonus in 
adults (PERM)29. Can present with epileptic encephalopathy, rare in children (3 paediatric 
cases in literature, 2/3 responded well to immunotherapy 30).   
GAD65 Intracellular antigen. Paraneoplastic antibody, mainly associate with limbic encephalitis and 
stiff-person-syndrome in adults31. Rarely reported in children, invariably associated with poor 
outcome.32 
Acute Disseminated Encephalomyelitis  (ADEM) and Myelin oligodendrocyte antibodies (MOG-
Abs) 
Generalised or focal seizures are frequently seen in the presentation of Acute Disseminated 
Encephalomyelitis (ADEM), a CNS inflammatory demyelinating disease of childhood, 
characterised by encephalopathy, polyfocal CNS deficits and multifocal brain MRI lesions 33-35. 
Response to immunotherapy is good, and outcomes generally favourable, however, some patients 
may relapse 33. Whilst most children with ADEM go on to develop in line with their peers, up to 
43% show impairments in specific cognitive or behavioural domains. Although meta-analysis did 
not reveal overall differences, it seems that a subset of children appears to have ongoing cognitive 
(e.g. processing speed) or behavioural difficulties (internalizing symptoms) 36. Furthermore, earlier 
work raised concern that children with early onset (<5 years) were more likely to have significant 
social and cognitive impairments at follow up 37. 
 
Antibodies to the myelin-oligodendrocyte protein (MOG-Abs) have been identified in ADEM 
patients, and appear to predict a non-multiple sclerosis but multiphasic disease course 38, 39. MOG-
ab associated disease includes adult cases of unilateral cerebral cortical encephalitis presenting 
with generalised epileptic seizures, with or without encephalopathy, which are responsive to anti-
epileptic drugs and immunotherapy 40. This highlights that MOG-Ab associated disease goes 
beyond white matter effects, with patients more likely to present with seizures as well as 
encephalopathy. With the relapsing nature of the disease spectrum associated with MOG-Abs, as 
well as the encephalitis and grey matter effects, there is concern that without early identification 
and treatment, there may be long lasting cognitive sequelae. This is of particular concern in 
paediatrics as there is a predilection for brain lesions in the younger age group (<9yrs) 27.  Recent 
cohort studies in both children and adults show that MOG-Ab associated disease is more likely to 
present with seizures, and incur an increased risk of  developing long-term “autoimmune epilepsy” 
41, 42. A recent UK study in MOG-Ab positive ADEM paediatric patients showed a trend towards 
a greater risk of post ADEM epilepsy associated with MOG-Abs, which may be the result of 
ongoing subclinical inflammation. This hypothesis was supported by the higher rate of intrathecal 
oligoclonal bands detected in these patients 42. MOG-Ab associated disease may reflect a true 
antibody-mediated epilepsy syndrome, and treatment may best be directed towards ameliorating 
the ongoing inflammation. Although studies show that 30% of children with MOG antibodies will 
relapse within 2 years 43, at the moment we cannot predict which children will relapse or recover, 
and we do not know how MOG-Abs directly contribute to the problems seen. Long-term cognitive 
problems are seen in up to 50% of children with MOG-Ab disease and brain involvement, but 
there are marked differences in both the progression of cognitive impairment and rate of 
accumulation of physical disability 44, 45.  
 
In ADEM, rehabilitation is focused on the motor impairment during the acute phase. Presentation 
with cognitive impairment can be late, and therefore the window of cognitive rehabilitation is often 
missed. Most studies make use of the EDSS (Extended Disability Severity Score) to measure 
outcome which is more representative of physical disabilities as opposed to cognitive problems, 
so underreporting of cognitive sequelae is a possibility. With the uncertainty surrounding whether 
or not a child with MOG-Abs will relapse, treatment and prognostication of these antibody positive 
cases is particularly challenging 39.  
 
Future challenges 
One of main prognostic and treatment challenges in children with immune-mediated and 
autoimmune epileptic encephalopathy is identifying those most at risk of severe disease and long-
lasting cognitive dysfunction when they first present. There is a pressing need to invest in 
collaborative cohort studies to track the natural history of disease and recognize the potential 
predictive features of poor outcome to facilitate timely effective therapeutic interventions. 
Although some studies show that affected children may be at a higher risk of long-term impairment 
than adults, the exact relationship between age of disease onset and eventual outcome is far from 
clear. Confounding factors include the late recognition of disease in children if the presentation is 
not typical causing a delay in treatment onset. The NEOS (anti-NMDAR Encephalitis One-Year 
Functional Status) score was developed using retrospective data from 382 NMDAR-Ab 
encephalitis patients to score affected patients within 4 weeks of initiating treatment and predicts  
the probability of good functional status at 1 year after initial symptom presentation 46. Treatment 
delay of more than 4 weeks, absence of improvement within 4 weeks of starting treatment, 
abnormal MRI, and elevated CSF white blood count were independent predictors for outcome and 
each assigned one point to construct the score. Although the score correlated with the probability 
of poor functional outcome at 1 year, patients with high NEOS scores at outset still progressed to 
recovery after 1 year. Therefore, functional status at one year did not represent the final clinical 
outcome, but was useful in delineating the speed of clinical improvement 46. The development of 
similar tools to predict ultimate clinical outcomes using prospective standardized patient datasets 
should be the aim of future trials. Consideration should also be given to including a qualitative 
component in long-term outcome studies, in order to capture patient and family perspectives at 
crucial time points during recovery 47. 
Immunotherapy is the mainstay of treatment for paediatric immune-mediated epileptic 
encephalopathy and aims to remove circulating neuronal autoantibodies or halt their production. 
Neuronal antibodies target ion channels and receptors (antigens), disrupting neuronal networks at 
a synaptic level during critical time points in a child’s development. There are, as yet, no available 
treatments that ameliorate the specific synaptic effects. This could also be contributing to the long-
term recovery of children with, for example, NMDAR-Ab mediated autoimmune epileptic 
encephalopathy. Pre-clinical studies in rodent models have shown promise in the use of agents that 
modulate the function of the NMDAR at the synapse 48-50, the future challenge will be to translate 
these findings to the bedside. Adjunctive individualised therapies that rescue the target antigen 
dysfunction may allow reduction in the amount of immunotherapy required, thereby minimising 
potential side-effects, and prevention of long-term cognitive problems. 
 
Finally, the increased use of advanced imaging and neurophysiology techniques may also help 
improve identification of underlying brain dysfunction and cognitive impairment early in the 
disease course. The use of resting state functional MRI and connectivity studies in NMDAR-Ab 
encephalitis 9, 51 show potential clinical utility, however translation to standard clinical practice is 
hampered by the small numbers and retrospective analysis. Another important tool for studying 
intrinsic brain activity is resting-state connectivity estimation with magnetoencephalography 
studies (MEG). Global connectivity analysis can highlight abnormal functional networks in 
different frequency bands. For example, in multiple sclerosis (MS) patients a lower functional 
connectivity in the alpha2 band and higher functional connectivity in the beta band have been 
recently found 52. More recently, using clinically applicable MEG-measures it has been 
demonstrated that there is a clinically relevant slowing of neuronal activity in MS patients in 
parietotemporal cortical areas and the thalamus, strongly related to cognitive impairment 53. These 
findings illustrate the relationship between thalamic atrophy, altered functional connectivity and 
clinical and cognitive dysfunction in MS, which could serve as a bridge to understand how 
neurodegeneration is associated with altered functional connectivity and subsequently clinical and 
cognitive decline. The application of resting-state MEG as a biomarker for cognitive disturbances 
in MS and other demyelinating diseases such as MOG-Ab disease in a clinical setting is therefore 
an increasing possibility.  
To date, no study has related the clinical, paraclinical, radiological and neurophysiological features 
at presentation to eventual neuropsychological and neurodevelopmental outcome in peadiatric 
patients with immune-mediated epileptic encephalopathy. This would enable early identification 
of children at risk, leading to better support and cognitive rehabilitation allowing children to reach 
their educational potential, later their vocational potential. Setting the expectations and maximising 
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